Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Expenses for 3 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 20.06% to $21.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.8 million through Dec 2025, up 32.98% year-over-year, with the annual reading at $89.8 million for FY2025, 32.99% up from the prior year.
  • Operating Expenses for Q4 2025 was $21.9 million at Artiva Biotherapeutics, down from $22.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $22.9 million in Q3 2025, with the low at $14.3 million in Q4 2023.
  • Average Operating Expenses over 3 years is $18.4 million, with a median of $18.3 million recorded in 2024.
  • The sharpest move saw Operating Expenses rose 5.67% in 2024, then surged 50.38% in 2025.
  • Over 3 years, Operating Expenses stood at $14.3 million in 2023, then increased by 27.56% to $18.3 million in 2024, then rose by 20.06% to $21.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $21.9 million, $22.9 million, and $22.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.